Mark Jones
Mark has dedicated his career to the development of antimicrobials. Originally trained as a clinical microbiologist at the University of Bristol Medical School, UK, Mark worked as a clinical scientist at the UK National Mycology Laboratory before moving to the University of Utrecht Medical Center, NL where he established a research group focusing on AMR projects across Europe. His career as a developer of new antimicrobials kicked off with what is today Eurofins, where he lead microbiology development programs for pharmaceutical clients. Since 2007 Mark has been part of Basilea Pharmaceuticals, Switzerland, where he is now Head of Development and specializing in the research and development of antibacterials and antifungals. With the Basilea team he has successfully brought ceftobiprole and isavuconazole to patients around the globe, and is now refocusing efforts to bring Fosmanogepix to clinics. Mark has published more than a 120 peer reviewed papers in the field of infectious disease and AMR and is a well known voice in today’s international AMR community; a Board Member of the BEAM Alliance and Board Member of the Swiss Round Table for Antibiotics.